Endocrinology

Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.

A Harvard-led analysis of more than 200,000 US adults found healthy plant-based diets lowered cardiometabolic risk regardless of ultra-processed food content.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

Clinicians discuss DKA risk, sick day plans, CGM use, and ketone testing in primary care.

Eden Miller, DO, and panelists discuss DKA recognition gaps, ketone testing barriers, and the future of dual glucose-ketone sensing.

SLEEP 2026: A sleep expert discusses screening tools, referral pathways, and why sleep disorders matter for cardiometabolic health in primary care.

CGM prescribing in primary care was associated with lower HbA1c levels, fewer hospitalizations, and fewer ED visits among insulin-treated adults.

FDA approved teplizumab to help preserve insulin production in children with recent-onset stage 3 type 1 diabetes.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Retatrutide phase 3 trials showed reductions in weight, A1C, osteoarthritis pain, and sleep apnea severity.

New FLOW trial data presented at ERA 2026 showed semaglutide improved health-related quality of life in adults with type 2 diabetes and CKD.

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

FDA grants priority review to finerenone for adults with type 1 diabetes and chronic kidney disease based on FINE-ONE data.

A large claims analysis suggests most US patients with prediabetes receive annual diabetes screening, although methods were not peer reviewed.

Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.

The FDA cleared Tandem's Control-IQ+ as the first AID system approved for pregnancy in type 1 diabetes, backed by the CIRCUIT trial.

Two-year CAHtalyst Adult data show crinecerfont enabled sustained glucocorticoid dose reductions while maintaining androgen control in classic CAH.

Steven Nissen, MD, discusses new SURPASS-CVOT data showing reduced cardiorenal events and mortality with tirzepatide vs dulaglutide.

Time constraints in diabetes visits may limit preventive care. Strategies for PCPs to balance chronic disease and screening needs.

Are preventive services falling through the cracks in diabetes care? Why role confusion across providers matters for PCPs.

A sweeping review finds women with diabetes consistently miss key preventive and reproductive services—contraception, preconception counseling, cancer and STI screening—worldwide.

Women with diabetes receive less contraception, cancer screening, and preconception care, increasing risk for preventable complications.